Epilepsy, Attention-Deficit/Hyperactivity Disorder and Methylphenidate: Critical Examination of Guiding Evidence
Monidipa Ravi1, Abel Ickowicz1
1Department of Psychiatry, Hospital for Sick Children and University of Toronto, Toronto, Ontario.
Objective:
Attention-Deficit/Hyperactivity Disorder (ADHD) and epilepsy are commonly comorbid; yet in the psychiatric literature, there is a remarkable paucity of guiding evidence regarding the safety and efficacy of treatment using methylphenidate (MPH) in this population. The objective of this review is to critically appraise evidence regarding the treatment of ADHD in the context of seizure disorders in order to better inform management considerations and practices.
Method:
A comprehensive search of the Central, Embase, Medline, and Web of Science databases identified 349 references. After a thorough review, only nine relevant references contributing new information and providing reliable and interpretable data were identified; seven were prospective studies (two double-blind placebo controlled trials, five open-label trials) and two were retrospective reviews. Prospective studies were then reviewed in detail, critically appraised, and interpreted.
Results:
All studies reported no increase in seizure rates in a majority of participants after exposure to MPH. MPH was effective in treating ADHD symptoms. However, the following major limitations to the studies impede drawing confident conclusions: small sample sizes, lack of uniformity regarding seizure type and severity, seizure-free period pre-stimulant treatment, and low baseline seizure rates.
Conclusions:
Given the academic, social, emotional, and functional impact of untreated ADHD, a watchful approach to the use of MPH in children with stable epilepsy who are impaired by ADHD symptoms is justified.
More Related Videos
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
